Zydus Lifesciences gets EIR for oncology injectable manufacturing facility in Ahmedabad

22 Sep 2025 Evaluate

Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for a GMP follow-up inspection conducted at its oncology injectable facility located at SEZ1, Ahmedabad from June 9 to June 18, 2025. The EIR has classified the facility as Voluntary Action Indicated (VAI). 

The facility was earlier classified as an Official Action Indicated (OAI) in June 2024 which is now revised to Voluntary Action Indicated (VAI).

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×